

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 019633-000127US
Client Reference No.: NRC00072.1D1C5,
NRC IPSO 11382

On

TOWNSEND and TOWNSEND and CREW LLP

By:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GILBERT and WAKARCHUK

Application No.: 10/820,536

Filed: April 7, 2004

For: NUCLEIC ACIDS ENCODING
SIALYLTRANSFERASES FROM C.
JEJUNI

Confirmation No.: 8839

Examiner: Sheridan Swope

Art Unit: 1656

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 10/303,128, filed November 21, 2002 (Attorney Docket No. 019633-000112US).

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

08/23/2006 DENMANU1 00000026 201430 10820536


02 FC:1806 180.00 DA

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Beth L. Kelly
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:ath



Substitute for form 1449A (Rev. 07-05) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/820,536		
		Filing Date	April 7, 2004		
		First Named Inventor	Gilbert, Michel		
		Art Unit	1656		
		Examiner Name	Sheridan Swope		
Sheet	1	of	3	Attorney Docket Number	019633-000127US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	5,352,670	10-04-1994	Venot, et al.	
	AB	5,374,541	12-20-1994	Wong, et al.	
	AC	5,545,553	08-13-1996	Gotschlich	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AD	WO	92/16640		10-01-1992	The Scripps Research Institute		<input type="checkbox"/>
	AE	WO	96/32491		10-17-1996	Cytel Corp.		<input type="checkbox"/>
	AF	WO	99/49051	A1	09-30-1999	National Research Council of Canada		<input type="checkbox"/>
	AG	WO	00/46379	A1	08-10-2000	National Research Council of Canada		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/820,536
				Filing Date	April 7, 2004
				First Named Inventor	Gilbert, Michel
				Art Unit	1656
				Examiner Name	Sheridan Swope
Sheet	2	of	4	Attorney Docket Number	019633-000127US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AH	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Structures of Core Oligosaccharide Regions from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 241-249 (1994b)	<input type="checkbox"/>	
	AI	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Antigen Chains from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 250-255 (1994c)		
	AJ	ASPINALL, et al. " Chemical Structures of the Core Regions of Campylobacter Jejuni Serotypes O:1, O:4, O:23, and O:36 Lipopolysaccharides," European Journal of Biochemistry, Vol. 213, No. 3, pp. 1017-1027, (May 1993)		
	AK	ASPINALL, et al. "Lipopolysaccharides from Campylobacter Jejuni Associated with Guillain-Barré Syndrome Patients Mimic Human Gangliosides in Structure," Infection and Immunity, Vol. 62, No. 5, pp. 2122-2125, (May 1994)		
	AL	AUSUBEL et al. "Protein Expression" In: <u>Current Protocols in Molecular Biology</u> , Wiley and Sons, Inc. 1987, Chapter 16		
	AM	BELUNIS et al., "Biosynthesis of Endotoxin" J. Biol. Chem., 267: 9988-9997 (1992)		
	AN	GAUDINO et al., "A Novel and Efficient Synthesis of Neolacto Series Gangliosides 3'-nLM1 and 6'-nLM1 " J. Am. Chem. Soc., 116: 1149-1150 (1994)		
	AO	GILBERT et al., "Cloning of the Lipooligosaccharide α -2,3-Sialyltransferase from the Bacterial Pathogens Neisseria Meningitidis and Neisseria Gonorrhoeae", Journal of Biological Chemistry, Vol. 271, No. 45, pp. 28271-28276, The American Society for Biochemistry and Molecular Biology, Inc., USA, (November 8, 1996)		
	AP	GILBERT, et al., "Biosynthesis of Ganglioside Mimics in Campylobacter Jejuni OH4384," The Journal of Biological Chemistry, Vol. 275, No. 6, pp. 3896-3906, The American Society for Biochemistry and Molecular Biology, Inc., USA, (February 11, 2000)		
	AQ	ITO et al., "Synthesis of Bioactive Sialosides" Pure Appl. Chem., 65: 753 (1993)		
	AR	KUROKI, "Campylobacter jejuni Strains from Patients with Guillain-Barré Syndrome Belong Mostly to Penner Serogroup 19 Contain β -N-Acetylglucosamine Residues" Ann. Neurol., 33: 243-247 (1993)		
	AS	PARKHILL, et al. "The Genome Sequence of the Food-Borne Pathogen Campylobacter Jejuni Reveals Hypervariable Sequences," Nature, Vol. 403, pp. 665-668, (February 10, 2000)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/820,536
				Filing Date	April 7, 2004
				First Named Inventor	Gilbert, Michel
				Art Unit	1656
				Examiner Name	Sheridan Swope
Sheet	3	of	4	Attorney Docket Number	019633-000127US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	AT	PENNER, et al., "Diversity of Lipopolysaccharide Structures in Campylobacter Jejuni," The Journal of Infectious Diseases, Vol. 176, No. 2, pp. S135-S138, (December 1997)		
	AU	PRENDERGAST, et al., "Lipopolysaccharides from Campylobacter Jejuni O:41 Strains Associated with Guillain-Barré Syndrome Exhibit Mimicry of GM1 Ganglioside," Infection and Immunity, Vol. 66, No. 8, pp. 3649-3677, (August 1998)		
	AV	PRESTON, et al., "The Lipooligosaccharides of Pathogenic Gram-Negative Bacteria," Critical Reviews in Microbiology, Vol. 22, No. 3, pp. 139-180, (1996)		
	AW	SABESAN et al., "Combined Chemical and Enzymatic Synthesis of Sialyloligosaccharides and Characterization by 500-MHz 1H and C NMR Spectroscopy" J. Am. Chem. Soc., 108: 2068-2080 (1986)		
	AX	SALLOWAY, et al., "Miller-Fisher Syndrome Associated with Campylobacter Jejuni Bearing Lipopolysaccharide Molecules that Mimic Human Ganglioside GD3," Infection and Immunity, Vol. 64, No. 8, pp. 2945-2949, (August 1996)		
	AY	TOMB et al., "The complete genome sequence of the gastric pathogen <i>Helicobacter pylori</i> ", Swiss-Prot Accession No.: A64547, Alignment with SEQ ID NO:17		
	AZ	WAKARCHUK et al., "Functional Relationships of the Genetic Locus Encoding the Glycosyltransferase Enzymes Involved in Expression of the Lacto-N-neotetraose Terminal Lipopolysaccharide Structure in <i>Neisseria meningitidis</i> " J. Biol. Chem., 271: 19166-19173 (1996)		
	BA	WOOD, et al., "Cloning, Mutation and Distribution of a Putative Lipopolysaccharide Biosynthesis Locus in Campylobacter Jejuni," Microbiology, Vol. 145, No. 2, pp. 379-388, (February 1999)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.